CANOQ vs. NBSE, PXMD, LSDI, BJDX, HSDT, PRFX, NMRD, PBLA, INM, and ATNF
Should you be buying Cano Health stock or one of its competitors? The main competitors of Cano Health include NeuBase Therapeutics (NBSE), PaxMedica (PXMD), Lucy Scientific Discovery (LSDI), Bluejay Diagnostics (BJDX), Helius Medical Technologies (HSDT), PainReform (PRFX), Nemaura Medical (NMRD), Panbela Therapeutics (PBLA), InMed Pharmaceuticals (INM), and 180 Life Sciences (ATNF). These companies are all part of the "medical" sector.
NeuBase Therapeutics (NASDAQ:NBSE) and Cano Health (NYSE:CANOQ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, community ranking, media sentiment, valuation and risk.
In the previous week, NeuBase Therapeutics had 4 more articles in the media than Cano Health. MarketBeat recorded 4 mentions for NeuBase Therapeutics and 0 mentions for Cano Health. Cano Health's average media sentiment score of 0.97 beat NeuBase Therapeutics' score of 0.00 indicating that NeuBase Therapeutics is being referred to more favorably in the media.
12.4% of NeuBase Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cano Health shares are held by institutional investors. 7.9% of NeuBase Therapeutics shares are held by company insiders. Comparatively, 13.9% of Cano Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
NeuBase Therapeutics received 49 more outperform votes than Cano Health when rated by MarketBeat users.
NeuBase Therapeutics has higher earnings, but lower revenue than Cano Health. NeuBase Therapeutics is trading at a lower price-to-earnings ratio than Cano Health, indicating that it is currently the more affordable of the two stocks.
NeuBase Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Cano Health has a beta of -0.5, suggesting that its stock price is 150% less volatile than the S&P 500.
NeuBase Therapeutics has a net margin of 0.00% compared to NeuBase Therapeutics' net margin of -33.23%. Cano Health's return on equity of -99.74% beat NeuBase Therapeutics' return on equity.
Summary
NeuBase Therapeutics beats Cano Health on 9 of the 13 factors compared between the two stocks.
Get Cano Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for CANOQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CANOQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CANOQ vs. The Competition
Cano Health Competitors List
Related Companies and Tools
